Ayesta F J, Flórez J
Department of Physiology and Pharmacology, University of Cantabria, Santander, Spain.
Eur J Pharmacol. 1990 Jan 3;175(1):1-12. doi: 10.1016/0014-2999(90)90145-v.
Cross-tolerance to the respiratory depression induced by i.c.v. [D-Ala2,D-Leu5]enkephalin (DADLE) and by s.c., i.c.v. and i.v. morphine was studied in anesthetized rats that had been rendered tolerant to s.c. sufentanil (4 micrograms/h per 7 days). Tolerance induced by i.c.v. sufentanil was also compared during withdrawal and its absence. Tolerance was evaluated by estimation of the changes in both the maximum attained reduction of respiratory frequency (Emax) and the area under the time-course curve for the effects (AUC). In contrast to the failure to develop tolerance, as estimated with the Emax, after i.c.v. sufentanil in the absence of abstinence (tolerance index: 1.1), rats displayed significant degrees of cross-tolerance to i.c.v. morphine (3.6), i.c.v. DADLE (4.3) and s.c. morphine (6.6). No tolerance, however, was obtained to i.v. morphine. Tolerance to i.c.v. sufentanil in non-abstinent rats was not present when the Emax was considered but was when AUC was considered. During withdrawal animals showed tolerance as estimated with both the Emax and AUC. These results complement previous findings and show that the appearance of dissimilar degrees of cross-tolerance to different agonists depends not only on their intrinsic activities but also on their pharmacokinetic properties. These observations, along with the critical influence of withdrawal upon the manifestation of tolerance, support the need to distinguish between the development of the tolerance state and the degree of tolerance that can be expressed under specific conditions.
在对皮下注射舒芬太尼(每7天4微克/小时)产生耐受性的麻醉大鼠中,研究了对脑室内注射[D-丙氨酸2,D-亮氨酸5]脑啡肽(DADLE)以及皮下、脑室内和静脉注射吗啡所诱导的呼吸抑制的交叉耐受性。还比较了在撤药期间和无撤药情况下脑室内注射舒芬太尼所诱导的耐受性。通过估计呼吸频率最大降低幅度(Emax)的变化以及效应的时间进程曲线下面积(AUC)来评估耐受性。与在无戒断情况下脑室内注射舒芬太尼后未能产生耐受性(耐受性指数:1.1)不同,大鼠对脑室内注射吗啡(3.6)、脑室内注射DADLE(4.3)和皮下注射吗啡(6.6)表现出显著程度的交叉耐受性。然而,对静脉注射吗啡未产生耐受性。当考虑Emax时,非戒断大鼠对脑室内注射舒芬太尼不存在耐受性,但当考虑AUC时则存在耐受性。在撤药期间,动物在Emax和AUC评估中均表现出耐受性。这些结果补充了先前的发现,表明对不同激动剂不同程度交叉耐受性的出现不仅取决于它们的内在活性,还取决于它们的药代动力学性质。这些观察结果,连同撤药对耐受性表现的关键影响,支持了区分耐受性状态的发展和在特定条件下可表达的耐受程度的必要性。